Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Catherine Curran"'
Autor:
Elio Adib, Talal El‐Zarif, Rohit K. Jain, William P. Skelton IV, Dory Freeman, Catherine Curran, Elie W. Akl, Amin H. Nassar, Praful Ravi, Charlene Mantia, David J. Kwiatkowski, Toni K. Choueiri, Guru P. Sonpavde
Publikováno v:
BJUI Compass, Vol 3, Iss 2, Pp 169-172 (2022)
Externí odkaz:
https://doaj.org/article/76522c21149d4e469e8745761faf5c58
Autor:
Peter McAnena, Kahraman Tanriverdi, Catherine Curran, K. Gilligan, Jane E. Freedman, James A. L. Brown, Michael J. Kerin
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Breast cancer is the leading cause of cancer related death in women, with metastasis the principle cause of mortality. New non-invasive prognostic markers are needed for the early detection of metastasis, facilitating treatment de
Externí odkaz:
https://doaj.org/article/87a42f735c70488f966154094f16116e
Autor:
Sarah Abou Alaiwi, Amin H Nassar, Pier Vitale Nuzzo, Ronan Flippot, Bradley A McGregor, Lauren C Harshman, Gregory R Pond, Catherine Curran, Kerry L Kilbridge, Xiao X Wei, Toni Choueiri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundImmune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Although the incidence and prevalence of irAEs have been well characterized in the literature, less is known about the cumulative incidence rate
Externí odkaz:
https://doaj.org/article/f9a53e784a40492e874a776edb028735
Autor:
Sonja Khan, Cathy L Brougham, James Ryan, Arisha Sahrudin, Gregory O'Neill, Deirdre Wall, Catherine Curran, John Newell, Michael J Kerin, Roisin M Dwyer
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68753 (2013)
MicroRNAs are small non-coding RNA molecules that control gene expression post-transcriptionally, and are known to be altered in many diseases including breast cancer. The aim of this study was to determine the relevance of miR-379 in breast cancer.
Externí odkaz:
https://doaj.org/article/07c15205b97842b8a2579564e78c2490
Autor:
CATHERINE CURRAN VIGIER
Publikováno v:
CounterPunch; Jun2024, p1-4, 4p
Autor:
Matthew Mossanen, Amin H. Nassar, Samantha M. Stokes, Nieves Martinez-Chanza, Vivek Kumar, Pier Vitale Nuzzo, David J. Kwiatkowski, Judy E. Garber, Catherine Curran, Dory Freeman, Mark Preston, Kent W. Mouw, Adam Kibel, Toni K. Choueiri, Guru Sonpavde, Huma Q. Rana
Publikováno v:
Clinical Genitourinary Cancer. 20:568-574
The familial aggregation of bladder cancers has been observed, but the incidence and association of familial bladder cancer with germline pathogenic and likely pathogenic (P/LP) variants is unknown.A retrospective analysis was conducted of patients w
Autor:
Pier Vitale Nuzzo, Elio Adib, Nicole Weise, Catherine Curran, Tyler Stewart, Dory Freeman, Amin H. Nassar, Sarah Abou Alaiwi, Ziad Bakouny, Bradley A. McGregor, Toni K. Choueiri, Rakesh K. Jain, Rana R. McKay, Guru Sonpavde
Publikováno v:
Clin Genitourin Cancer
In this multicenter retrospective study, we studied the impact of the concurrent use of renin-angiotensin system inhibitors (RASi) on the outcomes of 229 metastatic renal cell carcinoma (mRCC) patients treated with immune-checkpoint inhibitors (ICI).
Autor:
Praful Ravi, Arvind Ravi, Irbaz B Riaz, Dory Freeman, Catherine Curran, Charlene Mantia, Bradley A McGregor, Kerry L Kilbridge, Chong-Xian Pan, Michelle Pek, Yukti Choudhury, Min-Han Tan, Guru P Sonpavde
Publikováno v:
The Oncologist. 27:e406-e409
Serial evaluation of circulating tumor DNA may allow noninvasive assessment of drivers of resistance to immune checkpoint inhibitors (ICIs) in advanced urothelial cancer (aUC). We used a novel, amplicon-based next-generation sequencing assay to ident
Autor:
Elie W. Akl, Elio Adib, Talal El‐Zarif, Toni K. Choueiri, Charlene Mantia, Rohit Jain, William Paul Skelton, Praful Ravi, Dory Freeman, David J. Kwiatkowski, Catherine Curran, Amin Nassar, Guru Sonpavde
Publikováno v:
BJUI Compass, Vol 3, Iss 2, Pp 169-172 (2022)
BJUI Compass
BJUI Compass
Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in FGFR2/3. Informat
Autor:
Syed A. Hussain, Catherine Curran, Giuseppe Di Lorenzo, Ruby Gupta, Pasquale Verolino, Moshe Chaim Ornstein, Petros Grivas, Archana Agarwal, Mehmet Asim Bilen, Jorge A. Garcia, Guru Sonpavde, Alexandra Drakaki, Pedro C. Barata, Gregory R. Pond, Jae-Lyun Lee, Ravindran Kanesvaran
Publikováno v:
Clinical Genitourinary Cancer. 19:425-433
PD1/L1 inhibitors are approved by FDA as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the ou